Bertrand Anz

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Carol Moreno, Richard Greil, Fatih Demırkan et al. · The Lancet Oncology · 2018 · 548 citations

Medicine, Oncology, Pharmacology +13

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

Medicine, Oncology, Pharmacology +12

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Carol Moreno, Richard Greil, Fatih Demırkan et al. · Haematologica · 2022 · 130 citations · Full text

Medicine, Oncology, Pharmacology +9

Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

Guillermo Garcia‐Manero, Guillermo Montalban‐Bravo, Jesús G. Berdeja et al. · Cancer · 2017 · 105 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

David S. Siegel, Gary J. Schiller, Christy Samaras et al. · Leukemia · 2020 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +12